Investigational Therapy Significantly Improves Survival in Patients with Prostate Cancer
June 4th 2021The addition of an investigational therapy to standard-of-care treatment was associated with a median overall survival of 15.3 months in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.
Read More
‘Great Deal of Work’ Still Needed to Reverse Increasing Rates of Several HPV-Related Cancers
May 20th 2021Almost 20 years of data indicate that the incidence of HPV-related cervical cancer is noticeably declining, however other cancers related to the virus continue, and are expected, to increase.
Read More
Updated Analysis Supports Evaluation of Second-Line Fedratinib to Treat Myelofibrosis
July 24th 2019Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.
Read More
Targeted Therapies for Advanced MCL May Improve Outcomes as Front-line Treatment
June 26th 2019Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.
Read More
Collection of Family Cancer History Is Suboptimal, Highlighting Need for Patient Reporting
June 24th 2019In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.
Read More